Actinium-225 Targeted Alpha Therapy

What is Actinium-225 Therapy?

Actinium-225 therapy is an advanced form of targeted alpha therapy. It uses a radioactive isotope, Actinium-225, attached to a molecule that can recognize specific targets on cancer cells. After binding to the target, Actinium-225 releases high-energy alpha particles over a very short distance.

How Does It Work?

The principle is precision targeting. In prostate cancer, Actinium-225 may be linked to PSMA-targeting molecules. PSMA is commonly expressed on many prostate cancer cells. Before treatment, patients usually undergo PSMA PET/CT imaging to confirm sufficient target uptake.

Which Patients May Be Considered?

Actinium-225 therapy may be considered in selected patients with advanced or metastatic cancer, especially selected metastatic castration-resistant prostate cancer cases, when standard treatment options have already been used or when the multidisciplinary team believes targeted alpha therapy may be appropriate.

Potential Advantages

• Targeted delivery to selected cancer cells.
• Short-range high-energy alpha particle effect.
• Potential option for selected advanced cancer patients.
• Useful in precision nuclear medicine programs.

Possible Side Effects

Possible monitored risks include dry mouth, fatigue, nausea, blood count changes, kidney function changes and salivary gland effects. Risk depends on dose planning, previous treatments and patient condition.

Required Documents

• Recent medical summary.
• Pathology report.
• PSMA PET/CT or relevant molecular imaging.
• Previous oncology treatment details.
• Recent blood tests, kidney and liver function tests.